Abstract:BACKGROUND:Multinodular goitre is common in women. Treatments for non-toxic multinodular goitre include surgery, levothyroxine suppressive therapy, and radioiodine. Radioiodine therapy is the only non-surgical alternative for non-toxic multinodular goitre. However, a high amount of radioiodine is needed to enable the thyroid nodules to adequately take up the radioiodine, because the multinodular goitre takes up a low amount of iodine. Recombinant human thyrotropin (rhTSH) has been used to increase radioiodine uptake and reduce thyroid volume of the multinodular goitre. Whether the improved reduction of the goitre resulting from rhTSH-stimulated radioiodine therapy is beneficial to the person remains controversial. OBJECTIVES:To assess the effects of recombinant human thyrotropin-aided radioiodine treatment for non-toxic multinodular goitre. SEARCH METHODS:We searched the CENTRAL, MEDLINE, Scopus as well as ICTRP Search Portal and ClinicalTrials.gov. The date of the last search of all databases was 18 December 2020. SELECTION CRITERIA:We included randomised controlled clinical trials (RCTs) comparing the effects of rhTSH-aided radioiodine treatment compared with radioiodine alone for non-toxic multinodular goitre, with at least 12 months of follow-up. DATA COLLECTION AND ANALYSIS:Two review authors independently screened titles and abstracts for relevance. Screening for inclusion, data extraction, and risk of bias assessment were carried out by one review author and checked by a second. Our main outcomes were health-related quality of life (QoL), hypothyroidism, adverse events, thyroid volume, all-cause mortality, and costs. We used a random-effects model to perform meta-analyses, and calculated risk ratios (RRs) for dichotomous outcomes, and mean differences (MDs) for continuous outcomes, using 95% confidence intervals (CIs) for effect estimates. We evaluated the certainty of the evidence using the GRADE approach. MAIN RESULTS:We included six RCTs. A total of 197 participants were allocated to rhTSh-aided radioiodine therapy, and 124 participants were allocated to radioiodine. A single dose of radioiodine was administered 24 hours after the intramuscular injection of a single dose of rhTSH. The duration of follow-up ranged between 12 and 36 months. Low-certainty evidence from one study, with 85 participants, showed uncertain effects for QoL for either intervention. RhTSH-aided radioiodine increased hypothyroidism compared with radioiodine alone (64/197 participants (32.5%) in the rhTSH-aided radioiodine group versus 15/124 participants (12.1%) in the radioiodine alone group; RR 2.53, 95% CI 1.52 to 4.20; 6 studies, 321 participants; moderate-certainty evidence in favour of radioiodine alone). A total of 118/197 participants (59.9%) in the rhTSH-aided radioiodine group compared with 60/124 participants (48.4%) in the radioiodine alone group experienced adverse events (random-effects RR 1.24, 95% CI 0.94 to 1.63; 6 studies, 321 participants; fixed-effect RR 1.23, 95% CI 1.02 to 1.49 in favour of radioiodine only; low-certainty evidence). RhTSH-aided radioiodine reduced thyroid volume with a MD of 11.9% (95% CI 4.4 to 19.4; 6 studies, 268 participants; moderate-certainty evidence). One study with 28 participants reported one death in the radioiodine alone group (very-low certainty evidence). No study reported on costs. AUTHORS' CONCLUSIONS:RhTSH-aided radioiodine treatment for non-toxic multinodular goitre, compared to radioiodine alone, probably increased the risk of hypothyroidism but probably led to a greater reduction in thyroid volume. Data on QoL and costs were sparse or missing.

COMBINATION OF MOLECULAR ADSORBENT RECIRCULATING SYSTEM AND RADIOIODINE FOR THE TREATMENT OF CONCURRENT HYPERTHYROIDISM AND SEVERE LIVER DYSFUNCTION: A RETROSPECTIVE COHORT STUDY.

Intratumoral injection of lipiodol pingyangmycin combined with thalidomide in treatment of recurrent advanced liver cancer

WITHDRAWN: Comparing the Prognostic Impact of 131I Or/and Artificial Liver Support System on Liver Function Failure Combined with Hyperthyroidism

Comparing the prognostic impact of 131I or/and artificial liver support system on liver function failure combined with hyperthyroidism

Molecular Adsorbent Recirculating System: Clinical Experiences in Patients with Acute and Acute on Chronic Liver Failure

Effect of Liver Dysfunction on Outcome of Radioactive Iodine Therapy for Graves' Disease.

A Clinical Study on the Treatment of Severe Hepatitis by a Combined Artificial Liver.

Application of the Molecular Adsorbents Recirculating System in Patients with Severe Chronic Viral Hepatitis B in Middle and End Stages

Recombinant Human Thyrotropin Plus Radioactive Iodine Among Patients With Thyroid Cancer

Combination of Ultrasound-Guided Percutaneous Microwave Ablation and Radioiodine Therapy in Benign Thyroid Disease: A 3-Month Follow-Up Study

Liver Support Therapy with Molecular Adsorbents Recirculating System in Liver Failure： a Summary of 252 Cases from 14 Centers in China

Recombinant Human Thyrotropin Plus Radioactive Iodine among Patients with Thyroid Cancer: A Noninferiority Randomized Clinical Trial.

Rare Renal Metastases from Differentiated Thyroid Carcinoma: Early Clinical Detection and Treatment Based on Radioiodine.

Unexplained Hyperthyroglobulinemia in Differentiated Thyroid Cancer Patients As an Indication for Radioiodine Adjuvant Therapy: A Prospective Multicenter Study

Clinical Study of Combined Application of Compound Mylabris Capsules and 3-Dimensional Conformal Radiotherapy (3-DCRT) in Advanced Primary Liver Cancer in Advanced

Iodine-125 Seeds Insertion with Trans-Arterial Chemical Infusion for Advanced Lung Cancer: a Meta-Analysis.

Clinical Study of Molecular Adsorbents Recirculating System in the Treatment of Severe Hepatitis Liver Failure

Clinical Analysis of 115 Cases of Hyperthyroidism Complicated with Liver Functional Damage

Recombinant Human Thyrotropin (Rhtsh)-Aided Radioiodine Treatment for Non-Toxic Multinodular Goitre.

The Safety and Short-Term Efficacy of Selective Internal Radiation Therapy Combined with Systemic Treatment for Unresectable Malignant Hepatic Tumors in Chinese Patients.

Clinical Effect of Iodine-125 Seed Implantation in Patients with Primary Liver Cancer and Its Effect on Th1/Th2 Cells in Peripheral Blood